Product category:
Laboratory and scientific manufacturing services
News Release from: PlasmidFactory
Edited by the Laboratorytalk Editorial
Team on 24 September 2007
Therapeutic vaccination against cat
fibrosarcoma
Preliminary results indicate that anti cancer immune therapy with Magnetofection reduces the relapse of cat fibrosarcoma from 75% to nearly 40%.
Imagna (immuno gene therapy with magnetic nanoparticles) has been founded by members of the Institute of Experimental Oncology Klinikum rechts der Isar (Technical University Munich), the Clinic of Small Animal Medicine of the Ludwig-Maximilians-Universitat, Bayer Schering Pharma, Chemicell, and PlasmidFactory to provide evidence for the usefulness of therapeutic tumour vaccination by the magnetofection technology in a clinical study in cats with fibrosarcoma This consortium is supported by a grant from the German Ministry of Education and Research (BMBF)
This article was originally published on Laboratorytalk on 15 Jan 2007 at 8.00am (UK)
Related stories
Minicircle-DNA workshop in Bielefeld, Germany
The upcoming event addresses to those scientists wanting to keep themselves updated with the recent advances in minicircle technology and its application in DNA vaccination and gene therapy
License to manufacture pDG helper/packaging vector
PlasmidFactory obtains worldwide license from the German Cancer Research Center DKFZ for the manufacture and marketing of pDG helper/packaging vectors for adeno-associated virus (AAV) production
Standard therapy for cat fibrosarcoma is surgical removal.
However, the tumour recurs in 75% of the patients within one year.
The Imagna team has used Magnetofection to guide cytokine genes directly into the tumor prior to surgical excision.
The idea was that the cytokine expression within the tumour mass might activate the immune system against the tumour so that tumour cells missed by the surgical procedure would be killed.
Additional studies are intended to confirm and extend these promising preliminary results and to take initial steps towards a future drug approval, firstly for the veterinary medicine.
The partners contribute with their different competences in the field of veterinary medicine, therapeutic anti cancer vaccination, DNA production, gene transfer and targeting, pharmaceutical manufacturing and regulation.
• PlasmidFactory: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
